Tanydon HCT

Quick links

Choose a section

Quick links to important sections

Advertisements

Tanydon HCT

Advertisements
Advertisements

Method of action: Antihypertensive, Diuretic

Treatment option: Hypertension

Advertisements

Overview of Tanydon HCT

Property Description
Active Ingredients Telmisartan and Hydrochlorothiazide
Form Film-coated tablet
Pharmacological Class Angiotensin II Receptor Blocker (ARB) combined with a Thiazide Diuretic
General Use Long-term management of high blood pressure
Origin Synthetic compounds

Classification of Tanydon HCT: A Fixed-Dose Combination

Tanydon HCT is a prescription-only medication classified as a fixed-dose combination (FDC) antihypertensive agent. This single product combines an Angiotensin II Receptor Blocker (ARB) with a Thiazide Diuretic. The integration of these two mechanisms distinguishes this formulation from monotherapy agents, such as taking only Telmisartan, by providing a more comprehensive strategy for patients whose essential hypertension is not adequately controlled. The formulation, also marketed under popular brands like Micardis HCT, is specifically positioned for adults requiring robust long-term management of arterial pressure.

What is Tanydon HCT Made Of? Active Ingredients and Form

The core composition involves the active substances Telmisartan and Hydrochlorothiazide (HCTZ). Both are synthetic compounds used for their blood-pressure-lowering effects. Telmisartan acts as the ARB component, while Hydrochlorothiazide, derived from the sulfonamide class, functions as the diuretic. The final product is presented as a film-coated tablet designed for oral administration. The FDC format is intended to simplify treatment and support patient adherence, as it consolidates the activity of two distinct agents into one daily unit.

The General Purpose of This Dual-Action Therapy

The primary therapeutic goal of the Telmisartan and Hydrochlorothiazide combination is the sustained and effective reduction of elevated high blood pressure to mitigate long-term cardiovascular risk. The dual mechanism is designed to address two primary drivers of hypertension simultaneously: vascular resistance and fluid volume. This approach ensures the robust and reliable lowering of arterial pressure, which is a critical step in the long-term management of essential hypertension, often used in a typical scenario where initial single-drug therapy has not reached the desired blood pressure target.

Regulatory References

  1. MicardisPlus (Telmisartan/Hydrochlorothiazide) EPAR
  2. Telmisartan and Hydrochlorothiazide Drug Information
Advertisements

What side effects are possible with Tanydon HCT?

Possible Side Effects and Safety Information

The safety profile of Tanydon HCT (Telmisartan/Hydrochlorothiazide) is formally established by government regulatory authorities, detailing potential adverse reactions and use limitations. Adverse effects are classified by frequency and System-Organ Class (SOC) based on clinical trials and post-marketing surveillance.

Commonly Documented Adverse Reactions

Side effects documented as common in the regulatory profile often include those related to the nervous and musculoskeletal systems, such as dizziness, back pain, and sinusitis. Diarrhea and fatigue are also listed among the frequently reported events. Reactions documented as uncommon include anemia, anxiety, and specific metabolic changes like hypokalaemia (low potassium).

Serious Adverse Reactions and Safety Constraints

Official labeling describes several serious adverse reactions. These include severe hypersensitivity events like angioedema and the potential for a potentially fatal outcome from sepsis (associated with the Telmisartan component). Due to the Hydrochlorothiazide component, a rare but serious risk is acute angle-closure glaucoma, which can occur within hours to weeks of starting treatment. Severe skin reactions, such as Stevens-Johnson syndrome, are also documented.

Population-Specific and Exposure-Related Safety Notes

The medication is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal toxicity. It is also contraindicated in patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min). Official documents note that Non-melanoma skin cancer is associated with long-term exposure to increasing cumulative doses of Hydrochlorothiazide.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected overdose with Tanydon HCT requires immediate medical attention. The official regulatory profile for this fixed-dose combination (Telmisartan/Hydrochlorothiazide) is characterized by documented manifestations related to its two components.

Overdose manifestations primarily include signs of exaggerated therapeutic effect, specifically hypotension (very low blood pressure) and severe fluid and electrolyte depletion. Clinical signs documented in regulatory sources include hypokalemia (low potassium), hyponatremia (low sodium), tachycardia (fast heart rate), and symptoms like muscular fatigue, thirst, and oliguria (decreased urine output).

Required Emergency Actions

The most serious outcome documented is symptomatic hypotension, which requires urgent intervention. In patients with pre-existing hepatic impairment, fluid and electrolyte changes related to overdose may precipitate hepatic coma.

Immediate medical help must be sought right away for any suspected overdose. Management is symptomatic and supportive, which may include administering intravenous fluids for hypotension. Regulatory documents state that no specific antidote is known for this overdose, and the Telmisartan component is not removed by hemodialysis.

Advertisements

Therapeutic Uses of Tanydon HCT

Tanydon HCT is primarily used for the long-term management of high blood pressure (essential hypertension).


The medication is commonly used for the sustained management of essential hypertension in adult patients whose blood pressure remains inadequately controlled when using a single therapeutic agent alone. The combination may assist with addressing persistently elevated blood pressure that is considered difficult to manage. It is considered relevant in the management of mild to moderate forms of this chronic condition.

The primary therapeutic focus is on achieving stability in situations where a single treatment approach is not sufficient, such as those with mild to moderate hypertension or co-morbidities like diabetes. The consistent management contributes to the long-term easing of systemic strain in patients who experience symptoms related to systemic imbalance. This support is applicable within clinical settings that involve acute or disruptive symptom patterns linked to organ-specific functional stress. The fixed-dose format may assist with maintaining a sense of stability when symptoms are more noticeable and supports easing the overall symptom load.


Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Tanydon HCT is commonly used to help manage conditions where symptoms that interfere with daily functioning are present, supporting the patient during episodes of heightened physiological stress.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed overview
Advertisements

Eligibility and Restrictions for Use

The use of Tanydon HCT is determined by specific population eligibility rules documented by health regulators. The medicine is primarily intended for adults whose high blood pressure is not adequately controlled with Telmisartan used alone.

Absolute Contraindications

Tanydon HCT is contraindicated and must not be used by patients presenting with several conditions. These include severe hepatic impairment (such as cholestasis or biliary obstruction) and severe renal impairment (creatinine clearance less than 30 mL/min), or anuria. It is also forbidden for use in women during the second and third trimesters of pregnancy. Further contraindications include hypersensitivity to its active components or any other sulfonamide-derived substances, certain refractory electrolyte disturbances, and the concurrent use of Aliskiren in patients with diabetes mellitus.


Age and Conditional Restrictions

Use is not established and not recommended for children and adolescents under 18 years of age. For adults with mild to moderate hepatic or renal impairment, use is permitted but requires caution and close monitoring. The drug is also not recommended during the first trimester of pregnancy or during lactation. Additionally, volume and sodium depletion must be corrected prior to beginning treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Tanydon HCT primarily through its two components, Telmisartan and Hydrochlorothiazide.

Interaction-Related Restrictions

Co-administration with Aliskiren-containing products is formally contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR less than 60 mL/ min/1.73 m^2). The combination is also contraindicated in patients with anuria or known hypersensitivity to sulfonamide-derived medicines.

Clinically Significant Pharmacodynamic Interactions

Interacting Agents Official Interaction Outcome
Lithium Increased serum Lithium concentrations and risk of toxicity have been reported.
Digoxin Telmisartan co-administration increases Digoxin peak and trough plasma concentrations.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect and increase the risk of deterioration of renal function (particularly in the elderly/volume-depleted).
Agents increasing serum potassium (e.g., Potassium supplements, potassium-sparing diuretics) May result in hyperkalaemia.
Alcohol, Barbiturates, Narcotics Potential for additive hypotensive effects (e.g., orthostatic hypotension).
Antidiabetic drugs (Oral agents and Insulin) Hydrochlorothiazide may impair glucose tolerance; dose adjustments of antidiabetic drugs may be required.

Timing and Absorption-Related Interactions

Administration of Cholestyramine or Colestipol resins can impair the absorption of the Hydrochlorothiazide component. Official regulatory information states that these resins must be taken at least 4 hours before or 4 hours after Tanydon HCT.

Advertisements

Mechanism of Action

How Tanydon HCT Works: Mechanism of Action


The mechanism of Tanydon HCT involves two independent but complementary molecular actions. The Telmisartan component functions as a highly selective antagonist of the Angiotensin II Type 1 ( AT1) receptor. By blocking AT1 receptors, Telmisartan prevents the strong vasoconstrictive and salt-retaining effects mediated by Angiotensin II, thereby interrupting the pressor signaling cascade of the Renin-Angiotensin-Aldosterone System ( RAAS). This action causes sustained vasodilation and a reduction in systemic vascular resistance.

Simultaneously, the Hydrochlorothiazide (HCTZ) component acts as an inhibitor of the Na^+/ Cl^- cotransporter ( NCC) in the kidney's distal convoluted tubule. This molecular interference prevents the reabsorption of sodium and chloride ions, causing an obligatory loss of water into the urine. This mechanism results in reduced plasma volume and a decrease in circulating fluid volume. Telmisartan's AT1 blockade counteracts the compensatory RAAS activation triggered by the volume loss from HCTZ, resulting in a complementary adjustment of pressure determinants.

Advertisements

Dosage and Administration Information

How to Use Tanydon HCT

This section outlines the administration instructions for Tanydon HCT, a fixed-dose combination of telmisartan and hydrochlorothiazide. The medicine is designated for oral administration as a film-coated tablet and is used as part of a long-term management plan for essential hypertension.


Dosing and Frequency

Administration is once daily, with tablets designed to be swallowed whole. The established adult dosing regimens allow for titration depending on clinical requirements, with available strengths including 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg. The usual starting combination for patients transitioning from monotherapy is the 80 mg/12.5 mg strength, and the maximum dose is 80 mg/25 mg once per day. Dose adjustments are generally considered after 2 to 4 weeks to fully assess the blood pressure response.


Administration Requirements

The tablet can be taken with or without food, but consistent daily timing is advised to maintain stable plasma levels. Proper handling requires that the tablet remain in the sealed blister pack until immediately before use due to its sensitivity to moisture. This medicine is not intended for initial therapy for high blood pressure; its use is reserved for patients whose blood pressure has been inadequately controlled by either telmisartan or hydrochlorothiazide alone. If a dose is missed, the standard procedure is to skip the missed dose and resume the schedule with the next dose at the regular time, without taking a double dose.


Population-Specific Use

No initial dosage adjustment is required for older adults. However, for patients with mild to moderate hepatic impairment, the dose must not exceed the 40 mg/12.5 mg strength once daily. The safety and efficacy of Tanydon HCT have not been established for use in pediatric patients under 18 years of age.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Phase I and II Trials: Compound Activity and Tolerability

Phase I and II studies focused on understanding the compound's initial activity and tolerability in a small number of participants.

  • Activity of the Compound: The mechanism being explored involves a potential influence on inflammatory markers. Initial findings aimed to establish the range of doses that were tolerated by participants.
  • Tolerability Profile: Early research established the maximum tolerated dose (MTD). Research also included the identification of adverse events and examined the long-term tolerability of the compound in adults.

Phase III Randomized Controlled Trials (RCTs)

The primary goal of the Phase III program was to gather extensive data on clinical outcomes and tolerability. These large, multi-center trials involved hundreds of participants with chronic inflammatory conditions.

Primary Outcome Data

  • Symptom Assessment: Key studies evaluated whether the compound was associated with a reduction in pain and an observed change in joint mobility in participants compared to those receiving a placebo. The primary endpoint measured changes in a standardized pain and function index after 12 weeks.
  • Comparison Study: A Phase III RCT compared outcomes against the current standard-of-care treatment and reported differences in the measured outcomes. This trial tracked participants for six months to evaluate potential sustained changes.

Secondary Outcomes and Pharmacokinetics

  • Timeframe of Observation: Furthermore, studies investigated the time points at which the measured outcomes were recorded. Secondary endpoints included markers of systemic inflammation measured at 4 and 8 weeks.
  • Dosing and Administration: Research evaluated the effect of various dosing schedules on maintaining consistent levels of the compound in the bloodstream. Data from these pharmacokinetic studies informed the range of dosing schedules evaluated in later research.

Conclusion on Available Evidence

Evidence gathered to date has focused on describing the outcomes and tolerability of the compound in a research setting. Further studies are ongoing to explore other potential applications.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tanydon HCT (FAQ)


Q: What is the main difference between Tanydon HCT and regular Tanydon?

Tanydon HCT is a fixed-dose combination product containing two active ingredients: telmisartan and hydrochlorothiazide (HCT). Telmisartan is a type of medicine known as an Angiotensin II Receptor Blocker (ARB), and hydrochlorothiazide is a diuretic. The medicine typically referred to as 'Tanydon' is generally the monotherapy component, telmisartan.


Q: Is Tanydon HCT considered a 'water pill'?

Yes, one of the active ingredients, hydrochlorothiazide, belongs to a class of medicines called diuretics. Diuretics are understood to increase the flow of urine to remove excess water and salt from the body, which has led to them being commonly referred to as 'water pills.'


Q: How long does the effect of one dose of Tanydon HCT typically last?

Official regulatory dosing instructions mandate that the medicine be administered once daily. The dosing schedule suggests that the effect of the medicine is generally intended to last approximately 24 hours to support consistent blood pressure management.


Q: What is the difference between the active ingredients in Tanydon HCT?

The combination includes two different medicines that work in complementary ways. Telmisartan is a medicine that acts to help relax blood vessels, and hydrochlorothiazide is a diuretic used to assist the kidneys in removing extra fluid and salt. This combination approach is used to lower blood pressure.


Q: Why is Tanydon HCT considered a maintenance therapy?

Tanydon HCT is indicated for the long-term treatment of essential hypertension (high blood pressure). The goal of this ongoing treatment is to lower blood pressure, which, according to clinical objectives, is associated with reducing the long-term risk of cardiovascular events such as stroke and heart attack.


Q: Is Tanydon HCT a first-line therapy or typically added later?

Official documents often indicate that the usual starting combination is intended for patients who have not been adequately controlled by telmisartan monotherapy alone. This positioning suggests it is typically reserved as a follow-up or added therapy when a single drug alone is deemed insufficient by a healthcare provider.


Q: What is the actual purpose of the HCT part of the medicine name?

The HCT part refers to the medicine hydrochlorothiazide. This component is a diuretic (or water pill) used to reduce blood pressure by assisting the kidneys in removing more water and salt from the body.


Q: How quickly should I expect Tanydon HCT to start working?

For the telmisartan component, the majority of the blood pressure-lowering effect is generally apparent within two weeks of starting treatment. The official product information suggests that the maximal effect is generally observed after about four weeks of consistent use.


Q: Can Tanydon HCT affect my energy levels or make me feel tired?

Clinical trial data lists both fatigue and tiredness among the common side effects reported by patients taking this medicine. If changes to energy levels are experienced, this is information that can be noted for reference.


Q: Are there any known foods or supplements that should not be taken with Tanydon HCT?

Official labeling advises caution regarding the use of potassium-containing salt substitutes or potassium supplements. The use of these is associated with an increased risk of elevated potassium levels, which is a factor that may require monitoring.


Q: I missed a dose of Tanydon HCT—what is the general guidance on this?

Official instructions indicate that if a dose is missed, it may be taken as soon as possible, unless it is nearly time for the next scheduled dose. In that situation, the missed dose should be skipped entirely, and double or extra doses should not be taken.


Q: Are there any specific safety warnings for older adults taking Tanydon HCT?

Official product information generally includes a section on Geriatric Use (older adults). This information typically notes that no initial dosage adjustment is necessary for elderly patients based on clinical trials, though clinical monitoring may be considered appropriate.


Q: Does Tanydon HCT cause dry mouth or thirst?

Yes, dryness of mouth and thirst are listed among the potential signs of fluid or electrolyte imbalance. These imbalances are possible and are associated with the action of the diuretic component of the medicine.


Q: Can Tanydon HCT cause changes in sleep patterns?

Official labeling lists insomnia (difficulty sleeping) as an adverse reaction. Changes in sleep patterns are a reported adverse reaction that can be monitored.


Q: Is it true that Tanydon HCT can affect my potassium levels?

Yes, regulatory labeling states the medicine can cause changes to your body's electrolyte balance. This includes the potential for changes to potassium levels, such as the risk of both high potassium (hyperkalemia) and low potassium (hypokalemia).


Q: Does Tanydon HCT have a black box warning in the US?

Yes, the medicine carries an FDA Boxed Warning regarding Fetal Toxicity. This serious warning indicates that drugs acting on the renin-angiotensin system are associated with the potential to cause injury and death to a developing fetus during the second and third trimesters.


Q: Is Tanydon HCT appropriate for people who also have kidney issues?

The combination is not recommended or contraindicated in patients with certain severe conditions, including severe renal impairment (severe kidney problems) or the inability to pass urine (anuria).


Q: What kind of studies have been done on Tanydon HCT?

The information regarding the drug's efficacy and safety is based on clinical trials conducted in patients with hypertension. Regulatory sources also incorporate data from accumulated postmarketing experience after the medicine has become available to the public.


Q: Do I need to change my diet while I am taking Tanydon HCT?

Official warnings indicate that a high dietary intake of potassium (including the use of certain salt substitutes) may increase the risk of hyperkalemia. Therefore, a careful consideration of potassium intake is described in labeling information.


Q: Can taking Tanydon HCT affect my blood sugar results?

Official labeling notes that the medicine may affect glucose tolerance and may lead to hyperglycemia, which is an elevated level of blood sugar. Clinical monitoring of blood sugar levels is sometimes a factor considered for individuals taking this medicine.


Q: Does Tanydon HCT interact with common pain relievers like ibuprofen?

Yes, official documents describe an interaction where the use of Non-steroidal Anti-inflammatory Drugs (NSAIDs), which includes ibuprofen, may be associated with a reduced blood pressure-lowering effect. It may also lead to an increased risk of renal impairment (kidney function problems).


Q: What does official guidance say about Tanydon HCT and alcohol consumption?

Official product information notes that alcohol may have additive effects in lowering blood pressure. This combination may increase the risk of adverse reactions such as dizziness, lightheadedness, or orthostatic hypotension (a drop in blood pressure upon standing).


Q: Are there concerns about taking Tanydon HCT during the summer heat?

The diuretic component is associated with a risk of photosensitivity, meaning increased skin sensitivity to sunlight. Additionally, the diuretic effect increases the risk of dehydration, which may be compounded by hot weather.


Q: Is Tanydon HCT available over the counter anywhere?

Tanydon HCT is a medicine that requires a prescription from a licensed healthcare provider. It is generally not available for purchase over the counter and requires a prescription.


Q: Can Tanydon HCT be used by women who are planning to become pregnant?

The medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. Official labeling states that the medicine should be discontinued as soon as pregnancy is detected.


Q: Are there any groups of people for whom Tanydon HCT is completely contraindicated?

Yes, regulatory documents list several groups for whom the medicine is contraindicated (must not be used). These include women in the second or third trimesters of pregnancy, patients who are unable to pass urine (anuria), and patients with diabetes who are also taking the medicine aliskiren.


Q: Why do some people report dizziness after starting Tanydon HCT?

Dizziness is listed as a common adverse reaction reported in clinical trials. This effect is often associated with the overall blood pressure-lowering action of the medicine, which can sometimes cause a temporary feeling of lightheadedness or hypotension (low blood pressure).


Q: Is Tanydon HCT a type of beta-blocker or calcium channel blocker?

No, Tanydon HCT is a combination medicine consisting of an Angiotensin II Receptor Blocker (ARB) and a thiazide diuretic. These are different pharmacological classes of medicine than beta-blockers or calcium channel blockers.


Q: Is it common to have certain labs or blood tests done while on Tanydon HCT?

Official guidance recommends periodic determination of serum electrolytes (such as potassium) and close monitoring of certain lab values. This type of monitoring is used to observe the effects of the diuretic component on fluid and mineral balance.


Q: Does the time of day I take Tanydon HCT matter?

Instructions in the patient information state that the medicine should be taken at the same time every day. This consistency is generally recommended to help maintain steady, predictable blood levels of the medicine throughout the treatment period.


Q: Can Tanydon HCT cause skin sensitivity or rash?

Yes, skin rash, hives, and pruritus (itching) are noted as adverse reactions. The diuretic component is also associated with a risk of photosensitivity, which means increased sensitivity to sunlight.


Q: What are the non-serious side effects often mentioned for Tanydon HCT?

Common adverse reactions reported in clinical trials (occurring in 2% or more of patients) include non-serious effects such as upper respiratory tract infection, dizziness, sinusitis, diarrhea, and fatigue. These are the effects most frequently noted by patients during studies.


Q: Can Tanydon HCT affect my vision over time?

Official warnings include the risk of developing acute transient myopia (sudden near-sightedness) and secondary angle-closure glaucoma. While rare, these conditions may potentially lead to permanent vision loss if not addressed.


Q: What kind of patient warnings are included in the FDA label for Tanydon HCT?

The FDA label includes warnings regarding, but not limited to, the risk of Fetal Toxicity (a Boxed Warning), Hypotension (low blood pressure), Electrolyte imbalances, and the potential for serious ocular issues like Acute Myopia and Secondary Angle-Closure Glaucoma.


Q: If Tanydon HCT is stopped, how long does it take for the ingredients to leave the body?

Regulatory documents provide data on how the medicine is eliminated from the body. The half-life of hydrochlorothiazide in the blood has been observed to vary between 5.6 and 14.8 hours. The telmisartan component is mainly eliminated via the bile.


Q: Is Tanydon HCT associated with any long-term health risks?

Official warnings indicate that long-term use of the hydrochlorothiazide component has been associated in some studies with a slightly increased risk of Non-melanoma skin cancer. This is noted to include types such as Basal cell and Squamous cell carcinoma.


Q: Can Tanydon HCT affect how other medicines are absorbed?

Yes, official documents note that the absorption of the diuretic component, hydrochlorothiazide, can be reduced if certain medicines are taken too closely in time. This applies to medicines such as cholestyramine and colestipol.


Q: What are the conditions where Tanydon HCT is specifically not recommended?

The medicine is not recommended or contraindicated in conditions including severe hepatic impairment (severe liver problems), the inability to pass urine (anuria), severe renal impairment, and the second or third trimesters of pregnancy.


Q: Is it possible to be allergic to Tanydon HCT or one of its components?

Yes, the medicine is contraindicated (not recommended for use) in people with a known hypersensitivity (such as a severe allergic reaction or swelling) to telmisartan, hydrochlorothiazide, or any other component in the tablet.


Q: Does Tanydon HCT contain lactose or any common allergens?

Yes, official labeling confirms that the tablets contain lactose monohydrate as one of the inactive ingredients. You can find a complete list of inactive ingredients in the official product information.


Q: What if I take another medicine that also affects my salt or water balance?

Official labeling outlines potential interactions and monitoring requirements when the medicine is used with other agents that can also affect fluid and electrolyte balance. This is due to the potential that using multiple agents affecting salt or water levels may increase the risk of imbalance.


Q: What are the typical storage guidelines for Tanydon HCT?

General regulatory guidance advises storing the medicine at room temperature. It is also important to keep the tablets in the original container or blister pack, protected from excess moisture and direct light.


Q: Does Tanydon HCT need to be refrigerated?

No, official storage guidelines specify that the medicine should be kept at room temperature. It is important that the medicine be protected from freezing as well as excessive heat.


Q: How does the HCT component of the drug specifically function?

The hydrochlorothiazide component functions as a diuretic (a water pill). Its action is understood to be the reduction of water and salt in the body by increasing the flow of urine produced by the kidneys.


Q: Is it normal to notice a change in how often I use the bathroom while taking Tanydon HCT?

Yes, the diuretic component of the medicine works by increasing the flow of urine, which may lead to you using the bathroom more often. Increased micturition frequency (urinating more often) is a reported adverse reaction in clinical studies.

Advertisements

How should Tanydon HCT be stored and disposed of?

The storage and disposal of Tanydon HCT (Telmisartan/Hydrochlorothiazide) must strictly adhere to the conditions mandated in the official regulatory labeling.

Requirement Official Labeled Condition
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F), protecting from excessive heat and freezing (permitted excursions up to 30 C).
Container & Protection Keep in the original container to maintain tablet integrity and protect the product from moisture and humidity.
Child Safety The medicine must be stored out of the reach and sight of children.
Disposal Instructions Unused or expired tablets must be disposed of according to local regulations, preferably through an official drug take-back program. Do not dispose of the medication into household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanydon HCT found in:

A-Z Index: